Source: Annual Congress 2008 - Diagnosis of tuberculosis: problems and perspectives

Abstract

Aim: To characterize the evolution of inflammation markers during tuberculosis treatment
Methods: The study group consisted of 135 recent diagnosed patients which associated tuberculosis and mild anemia and had the following demographic characteristics: mean age 50.03 +/- 11.75 years (max 73, min 18), 54.1% males, 58.5% from rural areas. Standard inflammation markers were determined at the treatment initiation point, one and two months later: erythrocyte sedimentation rate (ESR), C reactive protein (CRP), fibrinogen concentration (Fg), platelet count (Pt), leukocyte count (WCC). At the end of the study all but three subjects had negative sputum cultures.
Available data was analyzed using the one tailed paired samples t-test, after testing for normality. Pearson correlation coefficient and associated p values were computed for different parameters at different treatment milestones.
Results: Some statistically significant differences (p<0,05) are presented in the table.

Conclusion: Inflammation markers evolution during tuberculosis treatment suggests a potential role as effectiveness predictors. In order to accomplish this additional data is required especially about treatment failures dynamics.

Rating:

Share or cite this content

Citations should be made in the following way:
E. Popa, T. A. Cernomaz, R. Cernat (Iasi, Romania). Frequently used inflammation markers and their role in monitoring tuberculosis treatment. Eur Respir J 2008; 32: Suppl. 52, 2390

Member's Comments

No comment yet.

Related content which might interest you: Role of haptogobins genetically determined phenotypes in the development, treatment and prevention pulmonary tuberculosis Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 The role of systemic markers of inflammation in bronchiectasis. Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019 The role of inflammatory biomarkers like precursors of COPD stability during long-term follow-up Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Dynamics of inflammation biomarkers in drug sensitive tuberculosis and pneumonia Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Rimfampicin importance in tuberculosis treatment Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008 Role of cytokines in regulation of inflammatory and protective reactions in progression of pulmonary MDR tuberculosis Source: Annual Congress 2007 - New methods to diagnose tuberculosis infection and disease and problems in tuberculosis care Year: 2007 The importance of inflammatory markers in sarcoidosis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Systemic inflammation in COPD – a role for infection? Source: Research Seminar 2008 - Host-pathogen interactions in the lung: implications for treatment of respiratory infections and inflammatory lung diseases Year: 2008 The role of calcium metabolism assessment in the clinical setting of interstitial lung diseases Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016 Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting Source: International Congress 2016 – Airway biomarkers Year: 2016 Basic factors, influencing treatment efficacy of patients with newly detected sputum positive destructive lung tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004 The role of biomarkers and effectiveness of maintenance therapy in stable severe COPD Source: International Congress 2017 – COPD management Year: 2017 The role of biomarkers in the management of severe asthma Source: International Congress 2019 – Severe asthma guidelines: update 2019 Year: 2019 Biomarkers of systemic inflammatory response in patients with tuberculosis, combined with HIV infection Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016 Evaluating the use of the interferon-γ response to mycobacterium tuberculosis (MTB) specific antigens to diagnose latent tuberculosis infection in patients with chronic inflammatory joint and skin diseases Source: Annual Congress 2011 - Tuberculin skin tests, interferon-gamma release assays and beyond Year: 2011 The role of infections in the induction of asthma: genetic and inflammatory drivers Source: Annual Congress 2007 - PG24 - GRACE full-day course. From cough to asthma: the role of infection Year: 2007 Study of inflammatory markers in sputum positive patients of pulmonary tuberculosis and its response to anti-tubercular treatment Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016 Which is the most effective inflammatory marker in the diagnosis, severity and treatment follow-up of patients with pneumonia? Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 The clinical and bacteriological basis for initiating a specific treatment Source: Annual Congress 2006 - PG11 - Clinical highlights on tuberculosis Year: 2006